Cat. #152046
pJEK1 Alpha-Synuclein Vector
Cat. #: 152046
Availability: Please enquire for quantities and pricing
Target: Alpha-synuclein
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Dr Fiona Benson
Institute: Lancaster University
Tool Details
*FOR RESEARCH USE ONLY
- Tool name: pJEK1 Alpha-Synuclein Vector
- Description: pJEK1 is a derivative of pET15b with the human alpha-synuclein open reading frame cloned in via the Ndel and BamHI restriction sites. In this construct alpha-synuclein is expressed as a fusion protein with a six His tag. 2004 FASEB paper: this alpha-synuclein protein available here is cited as source (2) in the Methods section.
- Additional notes: Alpha-synuclein is expressed predominantly in the brain, where it is concentrated in presynaptic nerve terminals. The deposition of the abundant presynaptic brain protein alpha-synuclein as fibrillary aggregates in neurons or glial cells is a hallmark lesion in a subset of neurodegenerative disorders. These disorders include Parkinson's disease (PD), dementia with Lewy bodies (DLB) and multiple system atrophy, collectively referred to as synucleinopathies. Parkinson's disease (PD) is a common neurodegenerative disorder characterized by the progressive accumulation in selected neurons of protein inclusions containing alpha-synuclein and ubiquitin.
Target Details
- Target: Alpha-synuclein
Application Details
- Application notes: pJEK1 is a derivative of pET15b with the human alpha-synuclein open reading frame cloned in via the Ndel and BamHI restriction sites. In this construct alpha-synuclein is expressed as a fusion protein with a six His tag. 2004 FASEB paper: this alpha-synuclein protein available here is cited as source (2) in the Methods section.
References
- El-Agnaf et al. 2004. FASEB J. 18(11):1315-7. PMID: 15180968.
- A strategy for designing inhibitors of alpha-synuclein aggregation and toxicity as a novel treatment for Parkinson's disease and related disorders.
